Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.60 |
| ▸ | CNR2 | P34972 | 9/20 | 0.53 |
| ▸ | CNR1 | P21554 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347693 | 1.00 | PPARA (0.60) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL4920953 | 1.00 | PPARA (0.60) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL4245971 | 1.00 | PPARA (0.60) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL8347698 | 1.00 | PPARA (0.60) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL669179 | 0.91 | CNR2 (0.50) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL3308337 | 0.91 | PPARA (0.60) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL669177 | 0.91 | CNR2 (0.50) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL669178 | 0.91 | CNR2 (0.50) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL3308333 | 0.91 | PPARA (0.60) | PPARACNR2CNR1PPARGPPARD | |
| SCHEMBL10300846 | 0.91 | CNR2 (0.50) | PPARACNR2CNR1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200078333-A1 | Healthier Aging in Domesticated Animals | POSTREL RICHARD (US) | 2020-03-12 | — | — | US | claimed |
| US-20190029993-A1 | QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES | REVIGORON LLC | 2019-01-31 | — | — | US | claimed |
| US-20190030044-A1 | HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING | POSTREL RICHARD (US) | 2019-01-31 | — | — | US | claimed |
| WO-2018118197-A1 | HEALTHIER AGING IN DOMESTICATED ANIMALS | POSTREL RICHARD (US) | 2018-06-28 | — | — | WO | claimed |
| US-20230404942-A1 | Life Extension and Quality of Life Improvement for Humans | POSTREL RICHARD (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230114740-A1 | Life Extension and Quality of Life Improvement for Humans and Other Mammals | POSTREL RICHARD (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220175694-A1 | Anti-Aging Therapy for Canines and Other Domesticated Animals | POSTREL RICHARD (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210228502-A1 | Anti-Aging Therapy for Canines and Other Domesticated Animals | REVIGORON LLC | 2021-07-29 | — | — | US | disclosed |
| US-20200078333-A1 | Healthier Aging in Domesticated Animals | POSTREL RICHARD (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190314325-A1 | Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management | POSTREL RICHARD (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190030044-A1 | HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING | POSTREL RICHARD (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190029993-A1 | QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES | REVIGORON LLC | 2019-01-31 | — | — | US | disclosed |
| WO-2018118197-A1 | HEALTHIER AGING IN DOMESTICATED ANIMALS | POSTREL RICHARD (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | LIPE, PNLIP, FAAH2 | PPARA 933/4885CNR2 460/4885CNR1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.